
Kimberly Chong
Examiner (ID: 8669, Phone: (571)272-3111 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1636, 1635, 1674 |
| Total Applications | 2007 |
| Issued Applications | 1153 |
| Pending Applications | 209 |
| Abandoned Applications | 674 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19505162
[patent_doc_number] => 12116574
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)
[patent_app_type] => utility
[patent_app_number] => 17/474949
[patent_app_country] => US
[patent_app_date] => 2021-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 26
[patent_no_of_words] => 17442
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17474949
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/474949 | Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C) | Sep 13, 2021 | Issued |
Array
(
[id] => 17611934
[patent_doc_number] => 20220154213
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => BOCAPARVOVIRUS SMALL NONCODING RNA AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/470560
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39273
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470560
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/470560 | None | Sep 8, 2021 | Issued |
Array
(
[id] => 19479787
[patent_doc_number] => 20240327829
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC
[patent_app_type] => utility
[patent_app_number] => 18/044945
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61603
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -49
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044945
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/044945 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Sep 8, 2021 | Pending |
Array
(
[id] => 18739905
[patent_doc_number] => 20230348872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/021469
[patent_app_country] => US
[patent_app_date] => 2021-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 78909
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -146
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021469
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/021469 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | Sep 7, 2021 | Pending |
Array
(
[id] => 18948321
[patent_doc_number] => 11891603
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-06
[patent_title] => Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA
[patent_app_type] => utility
[patent_app_number] => 17/466833
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 13830
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466833
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/466833 | Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA | Sep 2, 2021 | Issued |
Array
(
[id] => 18675574
[patent_doc_number] => 20230313187
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => MODIFICATIONS OF MAMMALIAN CELLS USING ARTIFICIAL MICRO-RNA TO ALTER THEIR PROPERTIES AND THE COMPOSITIONS OF THEIR PRODUCTS
[patent_app_type] => utility
[patent_app_number] => 18/044057
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62379
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -107
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044057
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/044057 | MODIFICATIONS OF MAMMALIAN CELLS USING ARTIFICIAL MICRO-RNA TO ALTER THEIR PROPERTIES AND THE COMPOSITIONS OF THEIR PRODUCTS | Sep 2, 2021 | Pending |
Array
(
[id] => 18127980
[patent_doc_number] => 11554176
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-17
[patent_title] => Compositions and methods of treating muscle atrophy and myotonic dystrophy
[patent_app_type] => utility
[patent_app_number] => 17/464607
[patent_app_country] => US
[patent_app_date] => 2021-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 74
[patent_figures_cnt] => 104
[patent_no_of_words] => 62263
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17464607
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/464607 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | Aug 31, 2021 | Issued |
Array
(
[id] => 17398232
[patent_doc_number] => 20220040322
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 17/464618
[patent_app_country] => US
[patent_app_date] => 2021-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65219
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17464618
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/464618 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | Aug 31, 2021 | Issued |
Array
(
[id] => 17554970
[patent_doc_number] => 11311627
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-04-26
[patent_title] => Nucleic acid-polypeptide compositions and methods of inducing exon skipping
[patent_app_type] => utility
[patent_app_number] => 17/463473
[patent_app_country] => US
[patent_app_date] => 2021-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 60
[patent_no_of_words] => 52051
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463473
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/463473 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | Aug 30, 2021 | Issued |
Array
(
[id] => 17458841
[patent_doc_number] => 20220072145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
[patent_app_type] => utility
[patent_app_number] => 17/463484
[patent_app_country] => US
[patent_app_date] => 2021-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51926
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463484
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/463484 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | Aug 30, 2021 | Issued |
Array
(
[id] => 17300081
[patent_doc_number] => 20210395920
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => METHODS AND MATERIALS FOR MULTIPLEXED COLLECTIONS OF FUNCTIONAL LIGANDS
[patent_app_type] => utility
[patent_app_number] => 17/460513
[patent_app_country] => US
[patent_app_date] => 2021-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17460513
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/460513 | Methods and materials for multiplexed collections of functional ligands | Aug 29, 2021 | Issued |
Array
(
[id] => 17444147
[patent_doc_number] => 20220064652
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => Treatment Of Sepsis With PCSK9 And LDLR Modulators
[patent_app_type] => utility
[patent_app_number] => 17/411460
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411460
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/411460 | Treatment of sepsis with PCSK9 and LDLR modulators | Aug 24, 2021 | Issued |
Array
(
[id] => 17533885
[patent_doc_number] => 20220112494
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-14
[patent_title] => IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA
[patent_app_type] => utility
[patent_app_number] => 17/410029
[patent_app_country] => US
[patent_app_date] => 2021-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17410029
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/410029 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | Aug 23, 2021 | Abandoned |
Array
(
[id] => 17688146
[patent_doc_number] => 20220195438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => OLIGOMERS
[patent_app_type] => utility
[patent_app_number] => 17/405439
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10584
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405439
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/405439 | OLIGOMERS | Aug 17, 2021 | Abandoned |
Array
(
[id] => 17428745
[patent_doc_number] => 20220056453
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => COMPOSITIONS AND METHODS TO TREATING HEMOGLOBINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 17/404576
[patent_app_country] => US
[patent_app_date] => 2021-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41995
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17404576
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/404576 | Compositions and methods to treating hemoglobinopathies | Aug 16, 2021 | Issued |
Array
(
[id] => 17256825
[patent_doc_number] => 20210369810
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => SELF-REPLICATING CELL SELECTIVE GENE DELIVERY COMPOSITIONS, METHODS, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/400984
[patent_app_country] => US
[patent_app_date] => 2021-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18606
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400984
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/400984 | Self-replicating cell selective gene delivery compositions, methods, and uses thereof | Aug 11, 2021 | Issued |
Array
(
[id] => 18786405
[patent_doc_number] => 20230374505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => Human XIST Antisense Oligonucleotides for X Reactivation Therapy
[patent_app_type] => utility
[patent_app_number] => 18/019720
[patent_app_country] => US
[patent_app_date] => 2021-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22814
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019720
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/019720 | Human XIST Antisense Oligonucleotides for X Reactivation Therapy | Aug 4, 2021 | Pending |
Array
(
[id] => 18597595
[patent_doc_number] => 20230272391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => ADAR DEPENDENT EDITING COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/018379
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -193
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018379
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/018379 | ADAR DEPENDENT EDITING COMPOSITIONS AND METHODS OF USE THEREOF | Jul 29, 2021 | Pending |
Array
(
[id] => 17399991
[patent_doc_number] => 20220042081
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => DETECTION OF ANALYTES BY ENZYME-MEDIATED STRAND DISPLACEMENT REACTIONS
[patent_app_type] => utility
[patent_app_number] => 17/444038
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13922
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17444038
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/444038 | Detection of analytes by enzyme-mediated strand displacement reactions | Jul 28, 2021 | Issued |
Array
(
[id] => 18675581
[patent_doc_number] => 20230313196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/017351
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9062
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017351
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/017351 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS | Jul 22, 2021 | Pending |